Psychedelic medicine has spent the better part of a decade accumulating clinical evidence. Now, according to Dane Stevens, the chief executive and co-founder of Optimi Health, it is running into a different problem: nobody has built the industrial infrastructure to deliver it safely at scale. The U.S. Food and Drug Administration held a hearing on September 14, 2026, drawing more than 80 speakers to discuss how a regulated therapeutic-delivery system for substances like psilocybin and MDMA might actually work, a sign that regulators are taking the question seriously even as the underlying science keeps piling up.
That science has been building since at least 2022, when a trial published in the New England Journal of Medicine found that a single 25-milligram dose of psilocybin reduced depressive symptoms in patients who had not responded to other treatments. A more recent study out of Oregon Health and Science University followed 346 participants across 24 licensed centers and found reductions in depression, anxiety, and PTSD symptoms, with nearly two-thirds of participants ranking the experience among the most meaningful of their lives. The stakes are large: roughly 62 million American adults live with a mental illness, about a third of major depressive disorder patients get no relief from medication, and first-line PTSD treatments fail to help around 40% of patients.
Optimi Health, a Canada-based manufacturer of pharmaceutical-grade psychedelic compounds that trades on Nasdaq under the ticker OPTH, has positioned itself as one of the companies trying to fill that infrastructure gap. The company says it has supplied more than 5,000 doses for research and clinical use across Australia, Canada, and the United Kingdom.
